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Introduction: This study aims to determine the prevalence of anti-SARS-CoV-2 antibodies among the employees 
of Islamabad Medical and Dental College and its allied hospital Akbar Niazi Teaching Hospital. 
Material and Methods: This descriptive cross-sectional study was conducted among the staff and faculty of 
Islamabad Medical and Dental College and its allied hospital, irrespective of their COVID-19 infection history. 
The study was approved by the institutional review board of Islamabad Medical and Dental College (Ref # 
37/IMDC/IRB-2020).  294 employees volunteered for the study from 23rd July to 30th July 2020 through Elecsys® 
Anti-SARS-CoV-2 (Immunoassay for the qualitative detection of IgG antibodies against SARS-CoV-2 in humans 
serum and plasma). SPSS was used for data analysis and a p-value <0.05 was considered significant. 
Results: Out of 284 volunteers, 87 (30.6%) were SARS-CoV-2 antibody positive, with the mean antibody level in 
seropositive individuals recorded as 24.44 ± 25.34. Among housekeeping and sanitary workers, 48.3% were 
seropositive while among lab technicians 37.1% were seropositive. After housekeeping and sanitary staff, the 
second most affected workers were lab technicians (37.1% were positive compared to 62.9% negative). Fever, loss 
of taste or smell, and breathing difficulty were the most significantly associated symptoms with COVID-19 
antibody seroprevalence as suggested by p-value 0.003, 0.004, and 0.032 respectively. Out of the 13 PCR positive 
participants (in the preceding 3 months), 10 (76.9%) showed positive antibodies in their serum and 3 (23.1%) had 
not developed antibodies. 
Conclusion: Seroprevalence of SARS-CoV-2 antibodies was estimated to be high among the healthcare staff, with 
the housekeeping and sanitary staff to be the most affected employees, probably due to the breach of personal 
protection. Fever, loss of taste or smell, and breathing difficulty were strongly associated with seropositivity of 
SARS-CoV-2 antibodies.  
Keywords: SARS-CoV-2, antibody testing, COVID-19, healthcare workers. 
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Introduction 
 
Since COVID-19 first emerged in Wuhan, China on 
December 12, 2019, it has played havoc and emerged 
as a massive pandemic. As of November 22, 2020, 
WHO has reported 57.8 million cases and 1.3 million 
deaths globally since this catastrophe hit the world. 
Pakistan along with Iran, Jordan, Morocco, Iraq, and 
Lebanon has reported the highest number of new cases 
in the Eastern Mediterranean Region.1 Clinically, 
COVID-19 manifestations include fever, dry cough, 
and fatigue, severe pneumonia in almost half of the 
patients, and acute respiratory distress syndrome in 
one-third of the patients.2 
Regarding diagnostic testing, two types of tests are 
being widely used across the globe. One type is 
molecular testing (Polymerase chain reaction) on a 
nasal or throat swab sample, which detects the 
presence or absence of genetic material (ribonucleic 
acid) of the virus. Another type of test detects the 
development of an immune response to the virus in 
the form of antibodies for example IgM, IgG, IgA 
produced by the body in response to infection. These 
antibody detection tests are not useful in the diagnosis 
and screening of early infection because the immune 
system requires time to counter the viral invasion, but 
they can have paramount importance in establishing 
the immune status of a population.3 Serology testing 
for COVID-19 antibodies is helpful to determine 
whether people had been previously exposed to SARS-
CoV-2.  SARS‐CoV‐2 is a member of the β‐coronavirus 
genus, with the sequence similarity being high (87.9% 
and 98.7%).  3 to 6 days after infection with SARS-
CoV-2, the level of IgM antibodies increases and 
becomes detectable, but then the levels rapidly 
diminish thereafter. Approximately 8 days after the 
appearance of symptoms, IgG antibodies form in the 
blood,  with progressively increasing levels over the 
course of infection and continue to rise for an extended 
period of time.4 In the absence of a vaccine, the 
buildup of  SARS-CoV-2 herd immunity through 
natural infection is theoretically possible.5,6 
The objective of this research is to carry out the 
antibody test against covid-19 among the employees of 
ANTH, IMDC, and allied health care professionals at 
Islamabad Medical and Dental College and its allied 
hospital Akbar Niazi Teaching Hospital (ANTH). 
There’s still a long way to go with both virus and 
antibody testing for COVID-19.  
This current study will attempt to piece together the 
complex puzzle of antibody-mediated immunity, 
aiming to achieve safe, effective, and sustained 
protection against this devastating disease. It is 
pertinent to investigate the level of SARS-CoV-2 
antibodies among healthcare staff who are the most 
exposed group in the community. It may help 
policymakers in making informed decisions in the 
light of evidence generated locally. 
 
Materials and Methods 
 
Study Design and Participants: It was a descriptive 
cross-sectional study conducted among the employees 
of Islamabad Medical and Dental College and its allied 
teaching hospital, Bhara Kahu, Islamabad. All 
members of the staff and faculty of Islamabad Medical 
and Dental College and allied hospital Akbar Niazi 
Teaching Hospital were encouraged to get tested for 
SARS-CoV-2 antibodies and 294 employees 
volunteered for the study. The healthcare workers 
included doctors, nurses, laboratory technicians, unit 
receptionists, housekeeping and sanitary workers, 
finance and administration staff. The study was 
approved by the Institutional Review Board of the 
institution. Informed consent was taken from all the 
participants explaining the objectives of the research 
and complete confidentiality and anonymity were 
ensured.  
Data Collection Procedure and details of Antibody 
Testing: A structured questionnaire was used to 
collect information about age, department, history of 
any symptoms during the past 3 months, and history 
of nasal or throat swab for COVID-19 if done. SARS-
CoV-2 antibody testing was done from 23rd July to 30th 
July 2020, through Elecsys® Anti-SARS-CoV-2 
(Immunoassay for the qualitative detection of IgG 
antibodies against SARS-CoV-2 in human serum and 
plasma). The assay was performed on Cobas e 411 
analyzers by Roche. Cutoff index of <1.0 was taken as 
non-reactive, while COI ≥ 1.0 was considered positive. 
The sensitivity of the kit ≥ 14 days post-PCR 
confirmation is 99.5%, while its specificity is 99.8% (as 
claimed by the manufacturers).  
Data Analysis: Data was analyzed through SPSS v.26. 
Mean and standard deviation was calculated for 
continuous variables and frequencies and percentages 
for categorical variables. A Chi-square test was used to 
find the relationship between antibody positivity and 
other variables, with a p value <0.05 taken as 
significant. 
Ethical Considerations: The study was approved by 
the institutional review board of Islamabad Medical 
and Dental College (Ref # 37/IMDC/IRB-2020). All 
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participants were informed about the objectives of the 




A total of 284 staff members were recruited. The mean 
age of the study participants was 30.8 ± 9.4 years. 
About 175 (61.6%) were males and 109 (38.4%) were 
females. Out of 284, 7 (2.5%) were from senior 
management, 52 (18.3%) were doctors, 31 (10.9%) unit 
receptionists, 93 (32.7%) were from the nursing 
department, 35 (12.3%) lab technicians, 29 (10.2%) 
housekeeping and sanitary workers, and 37 (13%) 
were from finance and admin department. Antibody 
testing was done from 23rd July to 30th July 2020 which 
showed that 197 (69.4%) were negative while 87 
(30.6%) came out antibody positive. The mean 
antibody level in the sample was 7.54 ± 17.94 while the 
mean antibody level in seropositive individuals was 
24.44 ± 25.35. During the COVID-19 pandemic, 
symptom analysis showed that 17 (6%) developed 
fever, 17 (6%) developed cough, 9 (3.2%) reported a 
loss of taste or smell, 3 (1.1%) reported diarrhea, while 
5 (1.8%) had difficulty breathing. About 255 (89.8%) 
developed none of these symptoms, while 29 (10.2%) 
showed one or more of these symptoms. Participants 
were also inquired about the month in which they 
developed the symptoms which showed that all of 
them showed the symptoms during the three months 
preceding our study.  
Table 1 depicts no significant difference between the 
various age and gender groups (p-value 0.642 and 
0.792 respectively). On inquiring about the symptoms, 
182 (71.4%) of the participants had no symptoms 
during the preceding 3 months and were antibody 
negative. While among those who had developed 
symptoms, 14 (58.3%) had also developed antibodies 
compared to 15 (51.7%) who were antibody negative at 
the time of the test (p-value 0.035). The mean antibody 
level in the participants with a history of symptoms 
was 11.98 ± 21.2 while it was 7.04 ± 17.51 among those 
who were asymptomatic. 
Table 1 Cross-tabulation of antibody test results 
with age, gender, symptoms, and department of 
study participants 
Variable Antibody level p-value 
Age Positive Negative 
25 and below 32 (28.8%) 79 (71.2%)  
 
0.642 
26-30 22 (37.3%) 37 (62.7%) 
31-35 14 (31.8%) 30 (68.2%) 
36-40 10 (32.3%) 21 (67.7%) 
>40 9 (23.1%) 30 (76.9%) 
Gender 
Male  55 (31.4%) 120 (68.6%) 0.792 
Female 32 (29.4%) 77 (70.6%) 
Any symptom in the preceding 3 months 
Yes  14 (48.3%) 15 (51.7%) 0.035* 










Doctors 9 (17.3%) 43 (82.7%) 
Unit 
Receptionists 
9 (29%) 22 (71%) 
Nursing 29 (31.2%) 64 (68.8%) 
Lab 
Technicians 




14 (48.3%) 15 (51.7%) 
On analyzing the department of the study participants, 
housekeeping and sanitary staff were found to be 
maximally affected (48.3%) followed by lab technicians 
(37.1%). After housekeeping and sanitary staff, the 
second most affected workers were lab technicians 
(37.1% were positive compared to 62.9% negative). 
Out of the nursing staff, 29 (31.2%) had positive 
antibodies, while 64 (68.8%) had negative antibodies 
(p-value 0.095) as shown below in Figure 1. 
 
Figure 1: SAR-CoV-2 seroprevalence among 
employees of IMDC and its teaching hospital 
Table 2 shows fever, loss of taste or smell, and 
breathing difficulty to be significantly associated with 
COVID-19 antibody seroprevalence as suggested by 
the p values 0.003, 0.004, and 0.032 respectively.  
92                                              Journal of Rawalpindi Medical College (JRMC); 2021; 25 COVID-19 Supplement-1: 89-93 
Table 2: Seroprevalence and symptoms of COVID-19 
among employees 
Symptoms Antibody level p-value 
Fever Positive Negative 
Yes 11 (64.7%) 6 (35.3%)  
0.003* No 76 (28.5%) 191 (71.5%) 
Cough 
Yes 5 (29.4%) 12 (70.6%) 0.575 
No 82 (30.7%) 185 (69.3%) 
Loss of taste or smell 
Yes  7 (77.8%) 2 (22.2%) 0.004* 
No 80 (29.1%) 195 (70.9%) 
Diarrhea 
Yes 2 (66.6%) 1 (33.3 %)  
0.195 No 85 (30.2%) 196 (69.8%) 
Breathing Difficulty 
Yes 4 (80%) 1 (20%) 0.032* 
No 83 (29.7%) 196 (70.3%) 
(*p-value < 0.05 depicts significant difference) 
 
54 study participants out of 284 also had their PCR test 
done in the 3 months preceding the study out of whom 
13 (24.1%) were positive at the time of the test and 41 
(75.9%) were negative. Out of the 13 PCR positive 
participants, 10 (76.9%) showed positive antibodies in 
their serum and 3 (23.1%) had not developed 
antibodies (among these 1 participants had been PCR 
positive only 10 days before the antibody test, while 
the other 2 were PCR positive 1.5-2 months before the 
antibody test). Out of the 41 participants who were 
PCR negative at the time of the PCR test, 12 (29.2%) 
got infected thereafter and developed antibodies. 
Among the 230 study participants who never had PCR 
test for COVID-19, 65 (28.2%) had positive antibodies 




Our study provides valuable insight into the SARS 
CoV-2 antibody positivity rate among healthcare 
workers, seroconversion in PCR positive individuals, 
and strongly suggestive symptoms of COVID-19. 
Healthcare workers are the most exposed individuals 
in this pandemic and large numbers of asymptomatic 
healthcare workers could be a potential source of 
infection for others. 
This study reveals the seroprevalence of SARS CoV-2 
antibody to be 30.6% among healthcare workers in a 
tertiary care hospital with maximum prevalence 
among housekeeping and sanitary workers (48.3%) 
followed by lab technicians (37.1%).  This is higher 
than studies conducted in hospital settings of other 
countries.7,8 This may be due to a breach of personal 
protective measures and a lack of awareness in the 
communities they come from. The low prevalence of 
antibodies among doctors in our study reflects that 
strict use of precautionary measures has an impact on 
infectivity, despite being maximally exposed to the 
patients coming to the hospital. In another study done 
among healthcare workers in a tertiary care hospital in 
New York City, 9.8% of the healthcare workers tested 
positive for antibodies. However, no significant 
difference was observed in SARS-Cov 2 antibody rate 
across various age groups, gender, and job titles. Our 
study also shows similar results with insignificant p-
values (0.642, 0.792, and 0.095 respectively).9 Lower 
seroprevalence among healthcare workers has been 
reported in studies carried out in other parts of the 
world.10,11,12 
In a study done in Sweden among healthcare workers, 
the most reported symptoms were headache, malaise, 
fever, loss of smell, cough, and loss of taste; while 
abdominal pain and dyspnea were reported less 
frequently. Symptoms with the strongest association to 
seroprevalence were anosmia, ageusia, and fever 
while the symptom of sore throat did not differ among 
seropositive and seronegative which is comparable to 
our results.13 Another study that offered insight into 
the experience of healthcare workers of a critically 
affected COVID-19 referral hospital in Italy reported 
fever (69.5%), followed by weakness (44.5%), loss of 
taste (36%), and loss of smell (40%) to be the most 
common symptoms.14 An observational cohort study 
was carried out in healthcare staff of the Capital 
Region of Denmark loss of taste or smell to be the most 
strongly associated symptom with seropositivity.15 A 
study conducted among Swiss hospital workers 
reported a history of fever and myalgia to be the most 
differentiating symptom between seropositive and 
seronegative participants.16 In our study, fever, loss of 
taste or smell, and breathing difficulty are strongly 
associated with seropositivity of SARS-Cov-2 
antibodies.  
A study assessing PCR positivity and humoral 
response in patients with COVID-19 in New York City 
reported that 37% of suspected SARS-Cov-2 infections 
seroconverted to the SARS-Cov 2 spike proteins after 4 
weeks. In the same study, out of the 624 confirmed 
SARS-Cov 2 participants, all had seroconverted to the 
SARS-Cov 2 antibodies after 4 weeks except three.17 In 
our study, out of the 13 participants who had been 
PCR positive, 3 (23.1%) had not developed antibodies. 
Among these three, 1 participant was probably 
negative for SARS-Cov 2 antibodies because her 
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antibody levels were checked 10 days after PCR 
positivity. 
A limitation of this study was the small sample size. 
Voluntary participation might have instigated 
selection bias in our sample. Many of the healthcare 
workers refusing to participate might have had a 
characteristic associated with an increased risk of 
COVID infection (being too busy at COVID-19 wards, 
for instance). Limited data is available on the accuracy 
of serology tests, which may result in over or 




Seroprevalence of SARS-CoV-2 antibodies was 
estimated to be high among the healthcare staff, with 
the housekeeping and sanitary staff to be the most 
affected employees, probably due to the breach of 
personal protection. Fever, loss of taste or smell, and 
breathing were strongly associated with seropositivity 
of SARS-CoV-2 antibodies.  
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